Johnson & Johnson (NYSE: JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs). TECNIS PureSee IOL is an extended depth of focus (EDOF) lens designed to support visual clarity and quality for patients undergoing cataract surgery.
The lenses offer range of vision, with excellent distance and intermediate vision with some near vision3*
They also offer low level of bothersome visual symptoms: 97% of patients reported no very bothersome visual disturbances.
“With the full U.S. availability of TECNIS PureSee IOL, we are expanding access to an important extended depth of focus option that reflects our commitment to innovation, visual quality, and patient satisfaction,” said Erin Powers, President, Surgical Vision, North America, Johnson & Johnson.
“Patients today want vision solutions that support how they live their lives every day. TECNIS PureSee IOL builds on the trusted TECNIS platform to help meet those expectations while giving surgeons greater flexibility to personalize care.”
The expanded U.S. availability of TECNIS PureSee IOL comes during Cataract Awareness Month, a time dedicated to raising awareness about this common and preventable cause of vision loss. Cataract surgery is one of the most common and safe procedures in the U.S., with a success rate of nearly 98%.
In a single procedure, TECNIS PureSee IOL addresses both cataract-related vision loss and the effects of presbyopia, which occurs when your eyes gradually lose the ability to see objects clearly up close.
JNJ shares $1.66 to $240.15.
Related Stories
